---
schema_version: "secwatch.filing_event.v1"
accession: "0001490978-25-000116"
form_type: "8-K"
ticker: "SDGR"
cik: "0001490978"
company_name: "Schrodinger, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:15:14.536006+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Schrödinger Q3 revenue up 54% to $54.3M; software growth 28%, FY guidance trimmed

## Summary
- Total revenue $54.3M (+54% YoY); software revenue $40.9M (+28%); drug discovery $13.5M.
- GAAP net loss narrowed to $32.8M from $38.1M; non-GAAP net loss $42.3M (was $63.7M).
- FY2025 software revenue growth guidance cut to 8-13% (from 10-15%); drug discovery raised to $49-52M.
- Shift to discovery-focused R&D; not advancing programs independently, expects ~$70M savings.
- SGR-1505 got Orphan Drug Designation; SGR-6016 selected as development candidate.

## SEC filing metadata
- accession: 0001490978-25-000116
- form_type: 8-K
- ticker: SDGR
- cik: 0001490978
- company_name: Schrodinger, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1490978/000149097825000116/0001490978-25-000116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1490978/000149097825000116/sdgr-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001490978-25-000116
- JSON: https://secwatch.observer/filing/0001490978-25-000116.json
- Plain text: https://secwatch.observer/filing/0001490978-25-000116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.